Nasdaq

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

Upon exercise of the option, Dyadic would receive a milestone payment in the mid-seven figures and Janssen would have the right to add additional non-exclusive targets to the collaboration. Dyadic ...
Seeking Alpha

Dyadic outlines 2026 product revenue growth and commercialization milestones while expanding partnerships

President & COO Joseph Hazelton indicated that since stepping into the President's role in June 2025, the company has accelerated its transition "from a development stage platform company into a ...

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term ...
Yahoo Finance

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE)-- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology ...
Hosted on MSN

DYAI: One Strain To Rule Them All

Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced second quarter 2025 results and held its first conference call under its new name. As we look ahead to the remainder of 2025, we expect ...
manilatimes

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ ...
The Globe and Mail

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

JUPITER, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a ...
Seeking Alpha

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and ...

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and ...
Mena FN

Dyadic And Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant Dnase I (Rnase-Free)

(MENAFN- GlobeNewsWire - Nasdaq) JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”,“we”,“us ...